ArticleJournal of cancer research and clinical oncology2016
Development of an oncological-multidimensional prognostic index (Onco-MPI) for mortality prediction in older cancer patients.
Article in Journal of cancer research and clinical oncology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 2 syntheses or guidelines pooled it, 59 citations in OpenAlex.
- Prevalence of multidimensional frailty and pre-frailty in older people in different settings: A systematic review and meta-analysis.Ageing research reviews · 2021Pooled it
- Practical Assessment and Management of Vulnerabilities in Older Patients Receiving Chemotherapy: ASCO Guideline for Geriatric Oncology.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2018Guideline
- A Phase II Trial of Older Adults With Metastatic Breast Cancer Receiving nab-Paclitaxel: Melding the Fields of Geriatrics and Oncology.Clinical breast cancer · 2019Trial
- Phase II trial of weekly Docetaxel, Zoledronic acid, and Celecoxib for castration-resistant prostate cancer.Investigational new drugs · 2016Trial
- Using the Geriatric Core Dataset (G-CODE) to predict mortality in older patients with cancer: development and external validation.British journal of cancer · 2026Article
- Validation of Onco-MPI and Geriatric-8 for predicting 2-year mortality in older Indian patients with breast cancer: a prospective observational study.Ecancermedicalscience · 2026Article
- Psychometric Validation of the Arabic FRAIL Scale for Frailty Assessment Among Older Adults with Colorectal Cancer.Healthcare (Basel, Switzerland) · 2025Article
- Beyond Treatment Decisions: The Predictive Value of Comprehensive Geriatric Assessment in Older Cancer Patients.Cancers · 2025Article
- Retrospective analysis of curative rectal cancer surgery outcomes in elderly patients.Scientific reports · 2025Article
- Organisation and management of multi-professional care for cancer patients at end-of-life: state-of-the-art from a survey to community and hospital-based professionals.Research in health services & regions · 2024Article
- Cancer mortality and competing causes of death in older adults with cancer: A prospective, multicentre cohort study (ELCAPA-19).Cancer medicine · 2023Article
- Impact of Medical Specialties on Diagnostic and Therapeutic Management of Elderly Cancer Patients.Geriatrics (Basel, Switzerland) · 2023Article
- Article
- Article
- External validation of the first prognostic nomogram for older adults with cancer.Therapeutic advances in medical oncology · 2023Article
- Integrating Geriatric Assessment Measures into National Cancer Institute Clinical Trials.Journal of the National Cancer Institute. Monographs · 2022Article
- Expert consensus to optimize the treatment of elderly patients with luminal metastatic breast cancer.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2022Review
- Treatment of Older Adult Patients with Glioblastoma: Moving towards the Inclusion of a Comprehensive Geriatric Assessment for Guiding Management.Current oncology (Toronto, Ont.) · 2022Review
- Predictors of Mortality in Patients with Advanced Cancer-A Systematic Review and Meta-Analysis.Cancers · 2022Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeA multidimensional prognostic index (MPI) based on a comprehensive geriatric assessment (CGA) has been developed and validated in independent cohorts of older patients demonstrating good accuracy in predicting one-year mortality. The aim of this study was to develop a cancer-specific modified MPI (Onco-MPI) for mortality prediction in older cancer patients.
methodsWe enrolled 658 new cancer subjects ≥70 years (mean age 77.1 years, 433 females, 65.8 %) attending oncological outpatient services from September 2004 to June 2011. The Onco-MPI was calculated according to a validated algorithm as a weighted linear combination of the following CGA domains: age, sex, basal and instrumental activities of daily living, Eastern Cooperative Oncology Group performance status, mini-mental state examination, body mass index, Cumulative Illness Rating Scale, number of drugs and the presence of caregiver. Cancer sites (breast 46.5 %, colorectal 21.3 %, lung 6.4 %, prostate 5.5 %, urinary tract 5.0 %, other 15.3 %) and cancer stages (I 37 %, II 22 %, III 19 %, IV 22 %) were also included in the model. All-cause mortality was recorded. Three grades of severity of the Onco-MPI score (low risk: 0.0-0.46, medium risk: 0.47-0.63, high risk: 0.64-1.0) were calculated using RECPAM method. Discriminatory power and calibration were assessed by estimating survival C-indices, along with 95 % confidence interval (CI) and the survival-based Hosmer-Lemeshow (HL) measures.
resultsOne-year mortality incidence rate was 17.4 %. A significant difference in mortality rates was observed in Onco-MPI low risk compared to medium- and high-risk patients (2.1 vs. 17.7 vs. 80.8 %, p < 0.0001). The discriminatory power of one-year mortality prediction of the Onco-MPI was very good (survival C-index 0.87, 95 % CI 0.84-0.90) with an excellent calibration (HL p value 0.854).
conclusionOnco-MPI appears to be a highly accurate and well-calibrated predictive tool for one-year mortality in older cancer patients that can be useful for clinical decision making in this age group.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.